Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications

EuroIntervention 2018;14:e603-e606 published online ahead of print July 2018 published online e-edition August 2018. DOI: 10.4244/EIJY18M07_2

Lucas Lauder
Lucas Lauder1*; Sebastian Ewen1, MD; Michel Azizi2,3, MD; Laura Mauri4, MD; Philipp Lurz5, MD, PhD; Melvin David Lobo6, PhD; Faisal Sharif7, MD, PhD; William Wijns8, MD, PhD; Costas Tsioufis9, MD; Felix Mahfoud1, MD
1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg/Saar, Germany; 2. Paris-Descartes University, Paris, France; 3. Assistance Publique-Hôpi

Introduction to the session

This summary report aims to capture the content of the session at EuroPCR 2018 that reviewed the implications for clinical practice of the SPYRAL HTN-OFF MED trial, in order to share a critical analysis of the trial and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.

What was known before SPYRAL HTN-OFF MED?

Hypertension is highly prevalent and is the most important single risk factor for cardiovascular morbidity and death1. Insufficient blood pressure (BP) control to target values and ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
A prospective multicenter randomized all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the TALENT trial

Latest news